Brainomix, a University of Oxford spinout and Parkwalk portfolio company, has won the AI Impact Award at the 2026 UK Tech Awards. The award recognises the real-world impact of Brainomix’s AI imaging technology in helping clinicians make more informed decisions and improving care for patients.
What is the AI Impact Award at the UK Tech Awards?
The AI Impact Award is one of the categories at the 2026 UK Tech Awards, and Brainomix’s win recognises the real-world impact of its AI technology. Brainomix was named winner for the impact its AI technology is having on clinical decision-making and patient care.
Who is Brainomix?
Brainomix is an Oxford University spinout using artificial intelligence to improve diagnosis and treatment decisions in stroke and lung disease. Founded on world-leading academic research, the company has developed technology that helps clinicians interpret medical imaging more quickly and accurately, supporting faster treatment decisions and better patient outcomes.
In Parkwalk’s Meet the Portfolio series, CEO and Co-Founder Dr Michalis Papadakis discusses the origins of Brainomix, the clinical challenge that inspired its creation, and the journey from university spinout to international healthcare company. The conversation explores how the team identified an unmet need within stroke care, how advances in AI are helping transform medical decision-making, and what it takes to build and scale a business based on cutting-edge science.
Their software helps clinicians make treatment decisions, mainly in stroke and lung disease. Its tools analyse scans such as CT and MRI and give clinicians fast, consistent information at the point of care.
The stroke platform, Brainomix 360 Stroke, covers non-contrast CT, CT angiography, CT perfusion and MRI. The company says e-ASPECTS, launched in 2016, was the world’s first fully automated AI imaging tool of its kind. Its lung product, e-Lung, is FDA cleared and launched in the US in 2024.
Why does this award matter for patients and clinicians?
Stroke is time-critical, and treatment decisions depend on how quickly clinicians can interpret brain scans. In 2024, around 100,000 people in the UK were expected to have a stroke. AI decision support gives clinicians near-real-time information on the extent and nature of brain damage, and results can be viewed remotely, which can help patients reach the right treatment sooner.
The AI Impact Award recognises that real-world impact: technology that is helping clinicians make more informed decisions and improving care for patients.
